Skip to main content

Table 3 Univariable and multivariable cox analysis of DFS before propensity matched analysis

From: Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis

Variable Univariable Multivariable
HR 95% CI P HR 95% CI P
Age (≥60/< 60, year) 1.240 0.765–2.010 0.382
Sex (Men/Women) 1.751 1.042–2.941 0.034 1.919 1.097–3.357 0.022
HBsAg (yes/no) 0.672 0.405–1.114 0.123
HCV antibody (yes/no) 0.782 0.108–5.636 0.807
AFP (≥20/< 20, ng/mL) 1.245 0.824–1.881 0.299
CEA (≥5/<5, ng/mL) 1.169 0.672–2.035 0.581
CA19–9 (≥37/<37, U/mL) 1.136 0.727–1.775 0.575
Liver cirrhosis, yes (%) 1.291 0.815–2.044 0.277
TB (≥17/< 17, μmol/L) 0.998 0.607–1.641 0.995
ALB (≥40/<40, g/mL) 0.771 0.499–1.191 0.241
ALT (≥35/<35, U/L) 1.741 1.154–2.267 0.008 1.676 1.050–2.677 0.031
γ-GT (≥40/<40, U/L) 1.811 1.116–2.938 0.016 1.105 0.653–1.870 0.711
PLT (≥10/< 10 103/μL) 0.856 0.529–1.382 0.524
Prothrombin time, median (range), s 1.417 0.845–2.375 0.186
Tumour size, cm 1.226 0.809–1.857 0.338
Tumour nodularities 1.056 0.918–1.215 0.442
Occlusion, min (< 20/≥20) 2.363 1.356–4.119 0.002 1.790 0.974–3.289 0.061
Macrovascular invasion (yes/no) 1.878 1.300–2.713 0.001 2.026 1.342–3.058 0.001
Microvascular invasion (yes/no) 1.084 0.654–1.797 0.754
Lymphoid metastasis (yes/no) 2.300 1.287–4.112 0.005 2.835 1.517–5.297 0.001
Extrahepatic metastasis (yes/no) 2.248 0.538–9.395 0.267
Preventive TACE (yes/no) 2.799 1.815–4.317 < 0.001 2.763 1.769–4.314 < 0.001
  1. HBsAg hepatitis B surface antigen, HCV hepatitis C virus, AFP α-fetoprotein, CEA carcino-embryonic antigen, CA19–9 carbohydrate 19–9, TB total bilirubin, ALB albumin, ALT alanine aminotransferase, γ-GT γ-glutamyl transpeptidase, PLT platelet, ALP alkaline phosphatase
\